{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:05Z","timestamp":1791216485261,"version":"4.1.0"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare Nepafenac effect on foveal thickness (FT), total macular volume (TMV), and BCVA after cataract surgery when added to the common regimen of topical steroids perioperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Scopus, EMBASE, the Cochrane Library, and ClinicalTrials.gov were searched systematically on April 28, 2022, for RCTs. Our primary outcome was the change in FT at final follow-up visits. We also considered FT at different follow-up durations, TMV, and visual outcome. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The individual trials were evaluated for quality utilizing the Cochrane Collaboration's risk of bias assessment tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four RCTs totaling 4716 eyes were eligible. A significant difference was found between Nepafenac group and control group in the change in FT at final follow-up visit (MD, \u221211.622; 95% Cl [\u221217.475, \u22125.769]), at one week follow-up visit (MD, \u22126.409; 95% Cl [\u221213.148, 0.330]), at one month follow-up visit (MD, \u22129.090; 95% Cl [\u221213.260, \u22124.919]), at two months (MD, \u22125.769; 95% Cl (\u221222.477, \u221210.939]), and at three-month follow-up visit (MD, \u221212.913; 95% Cl [\u221222.254, \u22123.572]). However, there was no significant difference between the two groups regarding change in TMV at final follow-up visit. Nevertheless, a significant difference was found between the two groups regarding post-operative BCVA only at three-month follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Topical Nepafenac in addition to topical steroid is superior to the common regimen of topical steroid alone perioperatively in the prevention of macular swelling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721251317652","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:35:30Z","timestamp":1739338530000},"page":"1421-1431","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Nepafenac role in macular swelling prevention and in visual outcome after cataract surgery \u2013 a systematic review and meta-analysis"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-3525","authenticated-orcid":false,"given":"Malaz","family":"Almasri","sequence":"first","affiliation":[{"name":"Department of Ophthalmology of County Emergency Hospital Cluj-Napoca, Cluj-Napoca, Romania"},{"name":"Department of Ophthalmology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-5111","authenticated-orcid":false,"given":"Amjad","family":"Ghareeb","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Damascus University, Damascus, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-271X","authenticated-orcid":false,"given":"Abdulrahman","family":"Ismaiel","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-8622","authenticated-orcid":false,"given":"Daniel-Corneliu","family":"Leucuta","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7886-2044","authenticated-orcid":false,"given":"Simona Delia","family":"Nicoara","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology of County Emergency Hospital Cluj-Napoca, Cluj-Napoca, Romania"},{"name":"Department of Ophthalmology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(04)00109-2"},{"key":"e_1_3_3_3_2","first-page":"81","article-title":"NSAIDs in treatment of retinal disorders","volume":"13","author":"Gallemore R","year":"2006","unstructured":"Gallemore R. NSAIDs in treatment of retinal disorders. Rev Ophth 2006; 13: 81\u201388.","journal-title":"Rev Ophth"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101463"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090140115033"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(99)00196-0"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.08.053"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71170-5"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000328"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30544-5"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2020.02.004"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.035"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.01.036"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308617"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007049015148"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S31902"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2013.12.023"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S4820"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.01.026"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2011.03.052"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.07.032"},{"key":"e_1_3_3_22_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01825-1"},{"key":"e_1_3_3_24_2","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston M","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019; 10: Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v049.i05"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.331.11644"},{"key":"e_1_3_3_30_2","first-page":"616","article-title":"Impact of topical nonsteroidal anti-inflammatory drugs in prevention of macular edema following cataract surgery in diabetic patients","volume":"11","author":"Alnagdy AA","year":"2018","unstructured":"Alnagdy AA, Abouelkheir HY, El-Khouly SE, et al. Impact of topical nonsteroidal anti-inflammatory drugs in prevention of macular edema following cataract surgery in diabetic patients. Int J Ophthalmol 2018; 11: 616\u2013622.","journal-title":"Int J Ophthalmol"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14513"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2017.1396615"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2020.12.09"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2012.04.034"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118799626"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211001275"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2019.1701686"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.10"},{"key":"e_1_3_3_39_2","first-page":"387","article-title":"Functional and anatomical evaluation of the effect of nepafenac in prevention of macular edema after phacoemulsification in diabetic patients","volume":"12","author":"Mokbel T","year":"2019","unstructured":"Mokbel T, Saleh S, Abdelkader M, et al. Functional and anatomical evaluation of the effect of nepafenac in prevention of macular edema after phacoemulsification in diabetic patients. Int J Ophthalmol 2019; 12: 387\u2013392.","journal-title":"Int J Ophthalmol"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0405-7"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305803"},{"key":"e_1_3_3_42_2","first-page":"1131","article-title":"Nepafenac and bromfenac versus a placebo in minimizing the incidence of pseudophakic cystoid macular edema after phacoemulsification. Original article","volume":"33","author":"ElSobky H","year":"2020","unstructured":"ElSobky H, Ahmed Madi H, Aziz M. Nepafenac and bromfenac versus a placebo in minimizing the incidence of pseudophakic cystoid macular edema after phacoemulsification. Original article. Menoufia Medical Journal 2020; 33: 1131\u20131138.","journal-title":"Menoufia Medical Journal"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1612_21"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2015.10.061"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S157738"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S4684"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026024409826"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X89775"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2015.10.009"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-013-0020-5"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25067"},{"key":"e_1_3_3_52_2","first-page":"1870","article-title":"An adenosine agonist and prostaglandin E1 cause breakdown of the blood-retinal barrier by opening tight junctions between vascular endothelial cells","volume":"33","author":"Vinores SA","year":"1992","unstructured":"Vinores SA, Sen H, Campochiaro PA. An adenosine agonist and prostaglandin E1 cause breakdown of the blood-retinal barrier by opening tight junctions between vascular endothelial cells. Invest Ophthalmol Visual Sci 1992; 33: 1870\u20131878.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.07.032"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251317652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721251317652","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251317652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:47:14Z","timestamp":1777405634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721251317652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/11206721251317652"],"URL":"https:\/\/doi.org\/10.1177\/11206721251317652","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}